For example, recent studies of anabolic agents, such as antisclerostin and antitransforming growth factor-beta (anti-TGFβ) antibody, in OI mouse models show improvement in both bone mass and bone strength and may ameliorate the phenotype of OI patients in the future [49]. The gene discussed is TGFB1; the disease is osteogenesis imperfecta.